Novel study designs to investigate the placebo response

被引:43
作者
Enck, Paul [1 ]
Klosterhalfen, Sibylle [1 ,2 ]
Zipfel, Stephan [1 ]
机构
[1] Univ Tubingen Hosp, Dept Psychosomat Med, Tubingen, Germany
[2] Univ Dusseldorf, Inst Clin Neurobiol & Med Psychol, Dusseldorf, Germany
关键词
study design; experimental research; placebo; IRRITABLE-BOWEL-SYNDROME; CLINICAL-TRIALS; PREDICTORS; DRUG; PAIN; POLYMORPHISMS; PERSPECTIVES; EXPERIENCE; DYSPEPSIA; HIDDEN;
D O I
10.1186/1471-2288-11-90
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
100404 [儿少卫生与妇幼保健学];
摘要
Background: Investigating the size and mechanisms of the placebo response in clinical trials have relied on experimental procedures that simulate the double-blind randomized placebo-controlled design. However, as the conventional design is thought to elucidate drug rather than placebo actions, different methodological procedures are needed for the placebo response. Methods: We reviewed the respective literature for trials designs that may be used to elucidate the size of the placebo response and the mechanisms associated with it. Results: In general, this can be done by either manipulation the information provided to the subjects, or by manipulation the timing of the drug applied. Two examples of each strategy are discussed: the "balanced placebo design" (BDP) and the "balanced cross-over design" (BCD) and their variants are based on false information, while the "hidden treatment" (HT) and the ""delayed response test" (DRT) are based on manipulating the time of drug action. Since most such approaches include deception or incomplete information of the subjects they are suitable for patient only with authorized deception. Conclusion: Both manipulating the information provided to subjects (BDP, DCD) or manipulating the timing of drug application (HT, DRT) allows overcoming some of the restrictions of conventional drug trials in the assessment of the placebo response, but they are feasible mostly in healthy subjects for ethical reasons.
引用
收藏
页数:8
相关论文
共 54 条
[1]
Behzadi Sharareh S, 2008, Recent Pat Drug Deliv Formul, V2, P209, DOI 10.2174/187221108786241633
[2]
Loss of expectation-related mechanisms in Alzheimer's disease makes analgesic therapies less effective [J].
Benedetti, F ;
Arduino, C ;
Costa, S ;
Vighetti, S ;
Tarenzi, L ;
Rainero, I ;
Asteggiano, G .
PAIN, 2006, 121 (1-2) :133-144
[3]
Autonomic and emotional responses to open and hidden stimulations of the human subthalamic region [J].
Benedetti, F ;
Colloca, L ;
Lanotte, M ;
Bergamasco, B ;
Torre, E ;
Lopiano, L .
BRAIN RESEARCH BULLETIN, 2004, 63 (03) :203-211
[4]
Methods of blinding in reports of randomized controlled trials assessing pharmacologic treatments:: A systematic review [J].
Boutron, Isabelle ;
Estellat, Candice ;
Guittet, Lydia ;
Dechartres, Agnes ;
Sackett, David L. ;
Hrobjartsson, Asbjorn ;
Ravaud, Philippe .
PLOS MEDICINE, 2006, 3 (10) :1931-1939
[5]
Placebo Response in Randomized Controlled Trials of Antidepressants for Pediatric Major Depressive Disorder [J].
Bridge, Jeffrey A. ;
Birmaher, Boris ;
Iyengar, Satish ;
Barbe, Remy P. ;
Brent, David A. .
AMERICAN JOURNAL OF PSYCHIATRY, 2009, 166 (01) :42-49
[6]
CANNER PL, 1980, NEW ENGL J MED, V303, P1038
[7]
Placebos and painkillers: is mind as real as matter? [J].
Colloca, L ;
Benedetti, F .
NATURE REVIEWS NEUROSCIENCE, 2005, 6 (07) :545-552
[8]
Overt versus covert treatment for pain, anxiety, and Parkinson's disease [J].
Colloca, L ;
Lopiano, L ;
Lanotte, M ;
Benedetti, F .
LANCET NEUROLOGY, 2004, 3 (11) :679-684
[9]
How prior experience shapes placebo analgesia [J].
Colloca, Luana ;
Benedetti, Fabrizio .
PAIN, 2006, 124 (1-2) :126-133
[10]
The Delayed-Start Study Design [J].
D'Agostino, Ralph B., Sr. .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (13) :1304-1306